Results 61 to 70 of about 524,523 (149)

Comparison of the pathogenicity of multiple SARS‐CoV‐2 variants in mouse models

Animal Models and Experimental Medicine, EarlyView.
We assessed the pathogenicity of various SARS‐CoV‐2 variants using two distinct mouse models. Our findings indicated that earlier variants, including WH‐09, Beta, and Delta, exhibited greater pathogenicity than later variants. Specifically, the Omicron variant demonstrated reduced pathogenicity, characterized by a shorter disease course and diminished ...
Qi Lv, Ming Liu, Feifei Qi, Mingya Liu, Fengdi Li, Ran Deng, Xujian Liang, Yanfeng Xu, Zhiqi Song, Yiwei Yan, Shuyue Li, Guocui Mou, Linlin Bao   +12 more
wiley   +1 more source

A mouse model of lung ischemia–reperfusion injury with reversible left hilar entrapment

Animal Models and Experimental Medicine, EarlyView.
A Novel Reversible Left Hilar Entrapment Model for Mouse Lung Ischemia‐Reperfusion Injury with Visual Tracheal Intubation and Live Knot Technique. Abstract Lung ischemia–reperfusion injury (LIRI), an acute lung injury syndrome triggered by lung transplantation or distal organ ischemia, has long been a difficult and hot issue in clinical research.
GuangDong Weng, Yao Chen, ShanQing Bao, ChengXin Zhang, WenHui Gong   +4 more
wiley   +1 more source

Roadmap to Nanomedical Applications: Nanotoxicology and In Vitro Guidelines for Lanthanide‐Doped Luminescence Nanothermometers

Advanced NanoBiomed Research, EarlyView.
Lanthanide‐based luminescence nanothermometry holds multifaceted potential for nanomedical applications, yet despite significant research advances, clinical translation of the engineered nanomaterials is still controversial and widely disputed. This is related to crucial nanotoxicological aspects that must be addressed at the preclinical level ...
Simona Premcheska, Andre G. Skirtach, Anna M. Kaczmarek   +2 more
wiley   +1 more source

Immediate Therapeutic Response to Vigabatrin in Lissencephaly‐Related Epileptic Spasms due to TUBA1A R402H Variant

American Journal of Medical Genetics Part A, EarlyView.
Toru Nagata, Takashi Shibata, Hiroki Tsuchiya, Mari Akiyama, Mitsuhiro Kato, Tomoyuki Akiyama, Toshiki Takenouchi   +6 more
wiley   +1 more source

Bioinspirierte Kationische Antimikrobielle Polymere

Angewandte Chemie, EarlyView.
Dieser Übersichtsartikel behandelt Membran‐aktive kationische Polymere mit antimikrobiellen Eigenschaften. Im Fokus stehen Aspekte wie die Polymerarchitektur, Stimuli‐responsive antimikrobielle Polymere sowie Synergien von Polymeren und anderen Verbindungen.
Heliya Javadi, Anne‐Catherine Lehnen, Matthias Hartlieb   +2 more
wiley   +1 more source

Development of a Novel Double‐Layered Wound Dressing Composed of Chitosan Film and Tigecycline‐Loaded Electrospun Polycaprolactone Nanofibers

Journal of Applied Polymer Science, EarlyView.
The antibacterial double‐layered wound dressing is fabricated using chitosan (CH) film as the contact layer and tigecycline (Tig)‐loaded poly(ε‐caprolactone) (PCL) nanofibers as the top layer. The CH film has a uniform morphology, and the PCL‐Tig nanofibers show a smooth, randomly oriented, and beadless structure.
Ş. Melda Eskitoros‐Togay, Y. Emre Bulbul, Adem Unal, Esma Yeliz Kaya, Nurcihan Çanga Oymak, Nursel Dilsiz   +5 more
wiley   +1 more source

Efficacy, Safety, Pharmacokinetics, and Immunogenicity of ABBV‐154 in Adults With Glucocorticoid‐Dependent Polymyalgia Rheumatica: A Phase 2, Randomized, Double‐Blind, Placebo‐Controlled Trial

Arthritis &Rheumatology, EarlyView.
Objective An unmet need exists for glucocorticoid‐sparing treatments for patients with polymyalgia rheumatica (PMR). The antibody‐drug conjugate ABBV‐154 comprises adalimumab conjugated to a glucocorticoid receptor modulator. We evaluated ABBV‐154 versus placebo in patients with glucocorticoid‐dependent PMR.
Robert F. Spiera, Valerie Devauchelle‐Pensec, Claire E. Owen, Federico Díaz‐González, Tsutomu Takeuchi, Edit Drescher, Jaclyn Anderson, Dilek Arikan, Ronilda D'Cunha, Julie Parmentier, Denise T. Kruzikas, Weihan Zhao, Yang Yang, Karen Stellpflug, Frank Buttgereit   +14 more
wiley   +1 more source

Long‐Term Safety and Efficacy of Mepolizumab in Eosinophilic Granulomatosis With Polyangiitis

Arthritis &Rheumatology, EarlyView.
Objective Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare, relapsing, inflammatory disease. Management of EGPA predominantly relies on oral corticosteroids (OCS), which are associated with many adverse effects. The phase 3 MIRRA trial demonstrated efficacy and safety of mepolizumab, anti‐interleukin‐5 biologic, for EGPA.
Michael E. Wechsler, Jared Silver, Gerhard Wolff, Robert G. Price, Rejina Verghis, Peter F. Weller, Peter A. Merkel, Paneez Khoury, on behalf of the EGPA Mepolizumab Open‐Label Extension study group, Arnaud Bourdin, Pascal Chanez, Anoop Chauhan, Vincent Cottin, Gerald Gleich, Berhnard Hellmich, Tomonori Ishii, David Jayne, Jean‐Emmanuel Kahn, Peter Kern, Nader Khalidi, Ina Koetter, Carol Langford, Amy Markezich, Paul Monach, Shamsa Naveed, Peter Oelzner, Kenneth Pinna, Xavier Puechal, Emory H. Robinette, Florence Roufosse, Reinhard Voll, Andrew Schafer, Kaharu Sumino, Masami Taniguchi, Phillip Lieberman   +34 more
wiley   +1 more source

Peripheral Biomarker Signatures in Rheumatoid Arthritis–Associated Interstitial Lung Disease

Arthritis &Rheumatology, EarlyView.
Objective Rheumatoid arthritis–associated interstitial lung disease (RA‐ILD) is a significant cause of morbidity and mortality among patients with RA, yet effective risk stratification for RA‐ILD is lacking. We sought to characterize unique peripheral blood biomarker signatures in RA that could improve RA‐ILD discrimination beyond clinical and genetic ...
Austin M. Wheeler, Joshua F. Baker, Thomas R. Riley IV, Tate M. Johnson, Yangyuna Yang, Punyasha Roul, Katherine D. Wysham, Grant W. Cannon, Gary Kunkel, Gail Kerr, Dana P. Ascherman, Paul Monach, Andreas Reimold, Scott Matson, Jill A. Poole, Michael J. Duryee, Geoffrey M. Thiele, Ted R. Mikuls, Bryant R. England   +18 more
wiley   +1 more source

Clinical Factors Associated With Pneumocystis Pneumonia Despite Its Primary Prophylaxis: When to Stop Prophylaxis?

Arthritis &Rheumatology, EarlyView.
Objective Although previous studies show that primary prophylaxis against Pneumocystis jirovecii pneumonia (PJP) is effective in patients with rheumatic diseases receiving immunosuppressive treatment, there is limited evidence regarding the optimal timing for prophylaxis withdrawal.
Ju Yeon Kim, Se Rim Choi, Jin Kyun Park, Eun Young Lee, Eun Bong Lee, Jun Won Park   +5 more
wiley   +1 more source